A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Secondary Endpoints

Eligibility Criteria

Inclusion Criteria: * Have at least 1 prescription claims for enzalutamide (National Drug Code \[NDC\]: 00469-0125-99, 00469-0625-99, 00469-0725-60), apalutamide (NDC: 59676-600-12, 59676-600-56, 59676-600-99) or darolutamide (NDC: 50419-395-01, 50419-395-72) during the index identification period. \-- The date of the earliest SGARI claim to occur during this period will be defined as the index date with the corresponding SGARI as the index treatment. * Have ≥1 diagnosis of prostate cancer (ICD-10 code C61.) during the overall baseline period. * Age ≥18 years and male gender on the index date. * Have continuous health plan enrollment with medical and pharmacy benefits for at least 6 months prior to the index date. * Have continuous health plan enrollment with medical and pharmacy benefits for at least 3 months after the index date and throughout the follow-up period. Exclusion Criteria: * Since patients should not be prescribed more than one SGARI when initiating treatment, patie…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source